Use of Topotecan in Patients With Refractory Acute Leukemia

Completed · Phase 2

Conditions studied: Non-Hodgkin's Lymphoma, Leukemia

In brief

The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The drugs being used in this study include drugs frequently used in treating such diseases (mitoxantrone and etoposide) as well as a newer drug that has also been shown to be effective (topotecan).

Key facts

Study ID

NCT00100477

Run by

US Department of Veterans Affairs

People needed

10

Starts

1998-08-01

Expected to finish

2001-06-01

Last updated by the study team

2013-09-25

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients in the following disease categories will be considered eligible for this study:
• Any acute leukemia beyond an initial attempt to induce a remission or after relapse
• Chronic Myelogenous Leukemia in Blast Phase
• Refractory Multiple Myeloma
• Refractory non-Hodgkin's and Hodgkin's Lymphoma
• Patients must be more than 14 days beyond prior myelotoxic chemotherapy
• Several other eligibility criteria apply.

You may not qualify if…

• None

Where it is running

• North Florida/South Georgia Veterans Health System — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.